Patents Examined by Irina Neagu
  • Patent number: 10800742
    Abstract: In accordance with one or more embodiments, the present invention provides a compound of formulas I, II, and III, for use in methods of inhibition of PBX1-DNA interaction in a mammalian cell or population of cells, and for use in the treatment of medical conditions including but not limited to cancers, developmental disorders, inflammatory disorders, autoimmune diseases, or neuro-degenerative disorders.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: October 13, 2020
    Assignee: The Johns Hopkins University
    Inventors: Tian-Li Wang, Ie-Ming Shih, Mark Vaal, Alexander Stoeck, Jin G. Jung
  • Patent number: 10722526
    Abstract: The present invention relates to a pharmaceutical composition for radioprotection or radiomitigation with respect to radiation-induced damage, the composition comprising a compound of Formula 1, or a pharmaceutically acceptable salt thereof or a solvate thereof.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: July 28, 2020
    Inventors: Yoon Jin Lee, Hae June Lee, Jae Kyung Nam, A Ram Kim, Kyeng Jung Kim
  • Patent number: 10716754
    Abstract: Provided herein are topical formulations. The topical formulation may comprise: (i) pregabalin, (ii) water, (iii) DMSO, (iv) a keto acid, and (v) and/or a fatty alcohol. The topical formulation may also comprise (i) pregabalin, (ii) DMSO, (iii) a keto acid and (iv) a fatty acid ester. It has been discovered that the combinations of DMSO with a keto acid such as levulinic acid and/or and a fatty acid ester such as lauryl lactate, or combinations of DMSO with a keto acid such as levulinic acid and/or with a fatty alcohol such as oleyl alcohol are excellent penetration enhancers and, as such, can be incorporated in a skin-applied formulation to facilitate administration of pregabalin.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: July 21, 2020
    Assignee: Tioga Research, Inc.
    Inventors: Edward Thomas Kisak, John Michael Newsam, Servet Buyuktimkin, Nadir Buyuktimkin
  • Patent number: 10675284
    Abstract: This invention relates to methods of treating B-cell malignancies using a combination of inhibitors of JAK1 and/or JAK2 and inhibitors of PI3K?.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: June 9, 2020
    Assignee: Incyte Corporation
    Inventors: Peggy A. Scherle, Xuesong Liu
  • Patent number: 10654799
    Abstract: The present invention relates to methods, formulations, and compositions for the treatment of biofilms. In particular, the application discloses isothiocyanate functional surfactants either alone or combination with adjunct agents to treat biofilms.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: May 19, 2020
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 10647720
    Abstract: The present application provides novel pyrimido-pyridazinone compounds and methods for preparing and using these compounds. These compounds are useful in treating inflammation in patients by administering one or more of the compounds to a patient. In one embodiment, the novel pyrimido-pyridazinone compound is of Formula (I) and R1 and R2 are defined herein.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: May 12, 2020
    Assignee: Asan BioSciences, LLC
    Inventors: Aranapakam Venkatesan, Roger Smith, Subramanya Hosahalli, Vijay Potluri, Sunil Kumar Panigrahi, Vishnu Basetti, Karunasree Kunta
  • Patent number: 10647668
    Abstract: A method for treating phytophotodermatitis including the steps of applying an isothiocyanate functional surfactant to an area affected by phytophotodermatitis, wherein said isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: May 12, 2020
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 10640464
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of keratin-based skin diseases. In particular, the application describes compositions and methods of treating a patient suffering from skin blistering comprising the use of phase II enzyme inducers and/or activity modifiers.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: May 5, 2020
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 10603297
    Abstract: A method treats patient with treatment resistant depression, adjunct to standard antidepressant treatment or as monotherapy. These patients will be identified by non-response to at least one pharmacological antidepressant treatment with a sufficient dose and over a sufficient period of time. Further, one embodiment of the method includes a procedure to identify patients who would benefit from a combination of standard antidepressants with the described compounds from the start of the treatment in order to maximize the likelihood of response. Another embodiment of the method combines the described compounds with forms of Magnesium salts in order to overcome longer term tolerability issues with the compounds.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: March 31, 2020
    Inventor: Harald Murck
  • Patent number: 10584099
    Abstract: The present invention accomplishes this by having multiple molecules of parent drugs attached to carrier moieties and by extending the period during which the parent drug is released and absorbed after administration to the patient and providing a longer duration of action per dose than the parent drug itself. Prodrug conjugates are suitable for sustained delivery of heteroaryl, lactam-amide-, imide-, sulfonamide-, carbamate-, urea-, benzamide-, acylaniline-, cyclic amide- and tertiary amine-containing parent drugs that are substituted at the amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties. The carrier groups of the prodrugs can be hydrophobic to reduce the polarity and solubility of the parent drug under physiological conditions.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: March 10, 2020
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Tarek A. Zeidan, Laura Cook Blumberg
  • Patent number: 10556013
    Abstract: Compositions and methods for increasing efficiency of cardiac metabolism are provided.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: February 11, 2020
    Inventor: Andrew D. Levin
  • Patent number: 10550122
    Abstract: Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including Pl3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: February 4, 2020
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Pingda Ren, Michael Martin, Paul Isbester, Benjamin S. Lane, Jason Kropp
  • Patent number: 10537523
    Abstract: A drinkable pharmaceutical solution includes telmisartan or a pharmaceutically acceptable salt, hydrate or polymorph thereof, where the telmisartan has a concentration of 1 to 10 mg/ml within the drinkable pharmaceutical solution, and the drinkable pharmaceutical solution has a pH of 10.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: January 21, 2020
    Inventors: Detlef Mohr, Stefan Lehner
  • Patent number: 10532983
    Abstract: Disclosed are derivative compounds of ELQ-300 that include an ester at position 4. These compounds have enhanced properties relative to ELQ-300. Also disclosed are pharmaceutical compositions comprising the compounds and methods of treating and preventing malaria infections involving administering the pharmaceutical compositions to the subject.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: January 14, 2020
    Assignee: Oregon Health & Science University
    Inventors: Michael Riscoe, Aaron Nilsen, Galen Miley, Rolf Winter, Sovitj Pou, Jane Xu Kelly, Rozalia Dodean
  • Patent number: 10532038
    Abstract: The invention relates to the use of selective agonists of beta-3 adrenergic receptors for the treatment and/or prevention of pulmonary hypertension.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: January 14, 2020
    Inventors: Borja Ibáñez Cabeza, Ana García-Álvarez, Valentín Fuster Carulla
  • Patent number: 10533012
    Abstract: (R)-pirlindole or its pharmaceutically acceptable salts, as well as pharmaceutical compositions comprising the same for use in the therapeutic treatment and prevention of pain.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: January 14, 2020
    Inventors: Augusto Eugénio Pardal Filipe, Pedro Filipe Eufrásio Pedroso, Susana Marques Almeida Pecorelli, Carlos Alberto Eufrásio Casimiro Caixado, Ana Sofia da Conceição Lopes, João Carlos Ramos Damil
  • Patent number: 10525052
    Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent, preferably two to ten times the molar amount of the active agent. In one embodiment the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: January 7, 2020
    Assignee: Collegium Pharmaceutical, Inc.
    Inventors: Jane Hirsh, Alison Fleming, Roman Rariy, Alexander Klibanov
  • Patent number: 10519161
    Abstract: The present invention includes compositions, methods of making and using novel carbapenem compounds including active agents, compounds, antibacterial agents, pharmaceutically acceptable salts of C1?-C1? di-substituted carbapenem compounds, C5? substituted carbapenem compounds, C6?-C6? di-substituted carbapenem compounds and combinations thereof.
    Type: Grant
    Filed: October 29, 2013
    Date of Patent: December 31, 2019
    Assignee: Southern Methodist University
    Inventor: John D. Buynak
  • Patent number: 10500194
    Abstract: Small molecule covalent inhibitors of DCN1 and compositions containing the same are disclosed. Methods of using the DCN1 covalent inhibitors in the treatment of diseases and conditions wherein inhibition of DCN1 provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: December 10, 2019
    Inventors: Shaomeng Wang, Haibin Zhou, Jianfeng Lu, Liu Liu, Jeanne Stuckey, Liangyou Rui, Yi Sun
  • Patent number: 10485798
    Abstract: Methylnaltrexone nasal formulations are discloses which provide improved bioavailability over oral dosage forms and improved patient compliance over injectable dosage forms. Also disclosed are methods of making the nasal formulations and methods of using, specifically to treat the side effects of opioid drug use, such as constipation, and other indications.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: November 26, 2019
    Assignee: APTAPHARMA INC.
    Inventor: Siva Rama K. Nutalapati